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Supplementary Figures  
 
Supplementary Figure 1. CNO administration showed dose dependent effects in mice injected 
with Cre independent and Cre dependent DREADDs.  
(A) CNO administration produced dose dependent decrease in chloroquine evoked scratching in 
hM3Dq injected mice (one-way ANOVA, 0.3 vs 1 mg/Kg, * P = 0.0144, N = 6 for 0.3 mg/kg, N = 
6 for 0.5 mg/kg and N = 15 for 1 mg/kg). (B) CNO administration produced dose dependent 
increase in chloroquine evoked scratching in hM4Di injected mice (one-way ANOVA, 0.3 vs 1 
mg/Kg, **P <0.0001, 0.5 Vs 1, *P = 0.0003; N = 6 for 0.3 mg/kg, N = 6 for 0.5 mg/kg and N = 14 
for 1 mg/kg). (C) CNO activation of vlPAG Vgat::hM3Dq neurons produced dose dependent 
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decrease in chloroquine evoked scratching (one-way ANOVA, *1 vs 3 mg/Kg, P = 0.034, ***1 vs 
5, P <0.0001,  #2 vs 3, P = 0.033, ##2 vs 5, P <0.0001; N = 8 for 1 mg/kg, N = 9 for 2 mg/kg, N 
= 6 for 3 mg/kg and N = 12 for 5 mg/kg). (D) CNO activation of vlPAG Vgat::hM4Di neurons 
produced dose dependent increase in chloroquine evoked scratching (one-way ANOVA, *1 vs 3 
mg/Kg, P = 0.021, ***1 vs 5, P <0.0001,  #2 vs 3, P = 0.0082, ##2 vs 5, P <0.0001; N = 8 for 1 
mg/kg, N = 10 for 2 mg/kg, N = 9 for 3 mg/kg and N = 8 for 5 mg/kg). (E) CNO activation of 
vlPAG Vglut2::hM3Dq neurons produced dose dependent increase in chloroquine evoked 
scratching (one-way ANOVA, 1 vs 5 mg/Kg, **P = 0.0059, 1.5 vs 5, *P = 0.0210; N = 7 for 1 
mg/kg, N = 7 for 1.5 mg/kg, N = 10 for 2 mg/kg and N = 12 for 5 mg/kg). (F) CNO activation of 
vlPAG Vglut2::hM4Di neurons produced dose dependent decrease in chloroquine evoked 
scratching (one-way ANOVA, 1 vs 5 mg/Kg, **P = 0.0005, 1.5 vs 5, ***P <0.0001,  2 vs 5, ##P  
= 0.0011; N = 8 for 1 mg/kg, N = 6 for 1.5 mg/kg, N = 14 for 2 mg/kg and N = 13 for 5 mg/kg). 









Supplementary Figure 2. Dose dependent chloroquine-induced conditioned place aversion. 
(A) Schematic of conditioned place aversion experimental design indicating saline- and 
chloroquine-paired chambers and the timing of each session. (B) Representative heat maps 
showing spatial location of a control mouse, pre and post chloroquine conditioning. (C) Upon 
conditioning mice for 3 days with saline/chloroquine treatment, difference scores indicate that 
mice spent less time in the chloroquine-paired chamber compared to the saline-paired chamber 
in a dose dependent manner. A dose of 50ug/50ul chloroquine injection into the nape of the 
neck did not produce any avoidance to saline or chloroquine chamber (N=5, t-test, t=0.1258, 
df=8, P=0.7864). While injecting dose of 200ug/50ul (N=6, t-test, t=2.785, df=10, P=0.0193) and 
400ug/50ul (N=16, t-test, t=0.1258, df=8, P=0.0002) chloroquine into the nape of the neck 
produced avoidance to the chloroquine paired chamber. * P=0.0193, *** P=0.0002. All values 







Supplementary Figure 3. Calcium dynamics of vlPAG Vgat+ neurons to spontaneous and 
chloroquine evoked scratching.  
(a) Quantification of Averaged Z score showing no significant differences in the Vgat Ca2+ 
dynamics between baseline and post spontaneous scratching bout. There is significant 
decrease in the Vgat Ca2+ activity when compared between spontaneous scratching and 
chloroquine evoked scratching, suggesting that the decreased activity of these neurons is 
critical during itch transmission in the PAG. (30 s pre- and post- scratch; t=2.147, df=4, 













Supplementary Discussion  
There were some notable discrepancies between our behavioral data obtained from 
pharmacological and chemogenetic manipulation of global PAG activity compared to cell-type 
specific PAG manipulations. First, global vlPAG inactivation by lidocaine infusion attenuated 
scratching behaviors, an effect that was not mimicked by global chemogenetic inhibition of 
vlPAG activity. In fact, global chemogenetic inhibition in the vlPAG enhanced scratching 
behavior, whereas chemogenetic activation of vlPAG suppressed scratching. This distinction 
can be explained by either a potential impact of lidocaine on axons of passage in the PAG, or by 
a predominant or epistatic effect of lidocaine on a specific cell type. Consistent with the latter 
concept, cell-type-specific chemogenetic inhibition of Vgat and Vglut2 neurons had opposing 
actions, where inhibition of Vglut neurons caused suppression of scratching and inhibition of 
Vgat neurons enhanced scratching behaviors. The overall effect of lidocaine therefore could be 
explained by a prominent role of inhibition of the Vglut2 neurons. Furthermore, activating Vgat 
neurons attenuated scratching, mimicking the effects of global PAG activation. It is tempting to 
speculate that these results can be explained by a microcircuit in the vlPAG, where Vgat 
neurons exert inhibitory control over Vglut neurons, which in turn provide descending 
projections that can enhance itch behaviors.  These results clearly highlight the differences in 
pharmacological, global and cell-type specific manipulations, and as such the behavioral 
outcomes using global pharmacological, electrophysiological, or other types of stimulation or 
inhibition need to be carefully interpreted. 
Global chemogenetic inhibition or activation of vlPAG neurons has the same effect on 
both pain1 and itch behaviors. Namely, global inhibition of the vlPAG potentiates both pain and 
itch while global activation of vlPAG neurons attenuates both pain and itch. These results are 
consistent with the hypothesis that the overall function of PAG output is to inhibit both pain and 
itch transmission. However, the results of experiments in which we selectively modulated 
activity of either GABAergic or glutamatergic neurons suggest that the mechanisms by which 
the PAG modulates pain and itch transmission are more complex, as presented schematically in 
Figure 10. Pain and itch are known to be processed distinctively at the spinal level. Using cell 
type specific chemogenetic manipulations, we found that activating GABAergic or inhibiting 
glutamatergic neurons in vlPAG causes suppression of itch and potentiation of pain 1, whereas 
inhibiting GABAergic or activating glutamatergic neurons causes potentiation of itch and 
suppression of pain behaviors. Our findings demonstrate that also at the midbrain level, vlPAG 
GABAergic neurons and glutamatergic neurons process both pain and itch signals inversely. 
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Thus, although pain and itch are processed and transmitted by similar neuroanatomical 
substrates at peripheral, spinal and supraspinal sites, they are discriminated and processed 
distinctly at the cellular level. 
We found that manipulating the activity of PAG neurons during chloroquine-evoked 
scratching leads to alterations in spinal cord activity, as we assessed using cFos expression 
studies, suggesting that vlPAG neurons modulate spinal pruritic processing.  The PAG forms 
strong connections with the amygdala, the habenula, several thalamic and hypothalamic nuclei, 
the RVM and the locus coeruleus 2, 3, 4, 5, 6, 7, 8, 9. We hypothesize based on prior work10 that PAG 
neurons might be modulating spinal cord activity via projections to RVM. In future studies, it will 
also be of great interest to determine which of these projection targets, or others, might mediate 
the differential modulation of pain and itch from glutamatergic and GABAergic projections from 
the vlPAG. The balance of activity in the vlPAG might lead to differential modulation of the 
activity in downstream projection targets and contribute to the inverse control of pain and itch 
processing in the spinal cord.  
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